InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Prime Medicine, Inc.

PRME Clue Score48
United States Fiscal year ends December CIK 0001894562
$3.99 +11.45% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.99 −54.19% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 20 Oct 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue5.2Operating income−0.9Net income−3.4EPS, diluted−1.91Fiscal year 2021Revenue0.0 −100.0%Operating income−84.5Net income−165.4EPS, diluted−14.19Fiscal year 2022Revenue0.0Operating income−116.5Net income−121.8EPS, diluted−4.19Fiscal year 2023Revenue0.0Operating income−204.8Net income−198.1EPS, diluted−2.18Fiscal year 2024Revenue3.0Operating income−202.5Net income−195.9EPS, diluted−1.65Fiscal year 2025Revenue4.6 +55.3%Operating income−208.4Net income−201.1EPS, diluted−1.35
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 5.2 0.0 0.0 0.0 3.0 4.6
Growth −100.0% +55.3%
Operating income −0.9 −84.5 −116.5 −204.8 −202.5 −208.4
Net income −3.4 −165.4 −121.8 −198.1 −195.9 −201.1
Growth
EPS, diluted −1.91 −14.19 −4.19 −2.18 −1.65 −1.35

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Operating margin−17.9%Net margin−65.5%Free cash flow margin−118.7%Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−6,787.4%Net margin−6,566.6%Free cash flow margin−4,363.4%Fiscal year 2025Operating margin−4,498.1%Net margin−4,342.4%Free cash flow margin−3,607.4%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −17.9% n/a n/a n/a −6,787.4% −4,498.1%
Net margin −65.5% n/a n/a n/a −6,566.6% −4,342.4%
Free cash flow margin −118.7% n/a n/a n/a −4,363.4% −3,607.4%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−5.5Capital expenditure−0.6Free cash flow−6.2Fiscal year 2021Operating cash flow−34.1Capital expenditure−4.2Free cash flow−38.2Fiscal year 2022Operating cash flow−131.8Capital expenditure−16.1Free cash flow−147.9Fiscal year 2023Operating cash flow−165.4Capital expenditure−8.7Free cash flow−174.1Fiscal year 2024Operating cash flow−122.9Capital expenditure−7.3Free cash flow−130.2Fiscal year 2025Operating cash flow−162.6Capital expenditure−4.5Free cash flow−167.1
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −5.5 −34.1 −131.8 −165.4 −122.9 −162.6
Capital expenditure −0.6 −4.2 −16.1 −8.7 −7.3 −4.5
Free cash flow −6.2 −38.2 −147.9 −174.1 −130.2 −167.1
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash37.0Shareholders’ equity2.3Fiscal year 2021Cash185.4Shareholders’ equity−156.2Fiscal year 2022Cash187.6Shareholders’ equity316.3Fiscal year 2023Cash41.6Shareholders’ equity133.1Fiscal year 2024Cash182.5Shareholders’ equity153.1Fiscal year 2025Cash63.0Shareholders’ equity120.9
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 37.0 185.4 187.6 41.6 182.5 63.0
Shareholders’ equity 2.3 −156.2 316.3 133.1 153.1 120.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021† 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
5.2 0.0 0.0 0.0 3.0 4.6
Growth −100.0% +55.3%
3.0 70.6 86.7 147.9 155.3 160.6
3.2 13.9 29.8 43.4 50.2 52.3
−0.9 −84.5 −116.5 −204.8 −202.5 −208.4
Growth
1.9 −0.5 −0.9 −0.3 0.0 0.0
−3.4 −165.4 −121.8 −198.1 −195.9 −201.1
Growth
Per share
−1.91 −14.19 −4.19 −2.18 −1.65 −1.35
−1.91 −14.19 −4.19 −2.18 −1.65 −1.35
Growth
2.6 13.0 33.9 91.0 118.6 148.8
2.6 13.0 33.9 91.0 118.6 148.8
Growth +391.5% +161.2% +168.4% +30.4% +25.4%

† The diluted share count jumps at 2021 and 2022 and 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue shrank 2.3% a year over five years.
  • Operating margin is down 4,480.2 points on five years ago, at -4,498.1%.
  • A net loss in 6 of 6 years on file.